Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod Phase 2 in Primary ITP
NCT03102593Phase 2Completed
- Sponsor
- argenx
- Start
- Mar 2017
- Primary completion
- Apr 2019
- Modality
- Antibody Fragments
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa in primary immune thrombocytopenia (ITP) (3 arms), sponsored by argenx. Primary endpoint: Incidence and severity of serious adverse events. Started Mar 2017; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03102593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102593.